Lidocaine Infusion in Pancreatic Cancer
ConditionPancreatic Cancer
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Illinois at Chicago
About this trial
This study elucidates the effects of the intravenous (IV) lidocaine infusion on the biology of pancreatic circulating tumor cells (CTCs) isolated from patients undergoing robotic pancreatectomy for all types of pancreatic cancer.
A prospective randomized controlled double blinded trial design will be used for the proposed study.
Eligibility criteria
Qualifiers
Has histologically or cytologically confirmed adenocarcinoma of the pancreas that is considered resectable as well as other types of pancreatic cancer (malignant endocrine and exocrine tumors)
Has measurable disease, defined as at least 1 tumor that fulfills the criteria
Patients diagnosed with resectable cancer, but upon initial phase of surgical exploration found to have metastatic disease
Has read, understood and signed the informed consent form (ICF) approved by the Independent Review Board/Independent Ethics Committee (IRB/IEC)
Disqualifiers
Has American Society of Anesthesiologists (ASA) physical status > 3
Has hypersensitivity or allergy to amide-linked local anesthetics
Has a second or third degree heart block
Has severe sinoatrial block
Trial design
Treatments tested in this trial
- Lidocaine Hydrochloride
- Saline Solution for Injection
Treatment groups
46 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov